Wafra Investment Advisory Group Inc. NY increased its stake in shares of Gilead Sciences (NASDAQ:GILD) by 4.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 116,211 shares of the biopharmaceutical company’s stock after buying an additional 4,960 shares during the period. Wafra Investment Advisory Group Inc. NY’s holdings in Gilead Sciences were worth $8,325,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in Gilead Sciences by 1.5% in the 4th quarter. BlackRock Inc. now owns 103,797,247 shares of the biopharmaceutical company’s stock valued at $7,436,033,000 after purchasing an additional 1,552,359 shares during the period. Bank of New York Mellon Corp boosted its holdings in Gilead Sciences by 1.5% in the 4th quarter. Bank of New York Mellon Corp now owns 30,542,928 shares of the biopharmaceutical company’s stock valued at $2,188,095,000 after purchasing an additional 446,263 shares during the period. Parnassus Investments CA boosted its holdings in Gilead Sciences by 2.5% in the 4th quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after purchasing an additional 464,609 shares during the period. Geode Capital Management LLC boosted its holdings in Gilead Sciences by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 15,849,063 shares of the biopharmaceutical company’s stock valued at $1,133,346,000 after purchasing an additional 379,867 shares during the period. Finally, Capital International Investors boosted its holdings in Gilead Sciences by 86.6% in the 3rd quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after purchasing an additional 5,205,983 shares during the period. 78.35% of the stock is owned by institutional investors and hedge funds.
A number of analysts have issued reports on the stock. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective for the company in a report on Monday, February 5th. Leerink Swann cut their price objective on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a report on Wednesday, February 7th. Maxim Group set a $94.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, February 6th. Bank of America upped their price target on shares of Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday, February 7th. Finally, Citigroup reaffirmed a “buy” rating and set a $105.00 price target (up previously from $103.00) on shares of Gilead Sciences in a report on Thursday, February 8th. Two analysts have rated the stock with a sell rating, nine have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $88.61.
In related news, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $83.51, for a total transaction of $2,087,750.00. Following the completion of the transaction, the executive vice president now directly owns 62,738 shares in the company, valued at approximately $5,239,250.38. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction that occurred on Friday, April 13th. The stock was sold at an average price of $75.56, for a total transaction of $440,741.48. Following the transaction, the director now owns 58,452 shares of the company’s stock, valued at $4,416,633.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 308,600 shares of company stock valued at $24,328,226. 1.16% of the stock is owned by corporate insiders.
GILD stock opened at $74.69 on Tuesday. The company has a market cap of $98,075.59, a P/E ratio of 8.73, a P/E/G ratio of -1.73 and a beta of 1.18. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.70 EPS. research analysts expect that Gilead Sciences will post 6.21 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 29th. Investors of record on Friday, March 16th were given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.05%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 26.64%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.